Neurocrine Reports Results of Valbenazine in P-III (KINECT-HD) Study for the Treatment of Chorea Associated with Huntington Disease
- The P-III (KINECT-HD) study evaluates the efficacy, safety & tolerability of valbenazine (qd) vs PBO in 128 adults aged 18 to 75yrs. with chorea associated with HD
- The study met the 1EPs i.e., reduction in chorea movements as measured by a change in the UHDRS TMC score from baseline to the avg. score @10 & 12wks. & a mean reduction in TMC score of 3.2 units while 2EPs of CGI-C Response Status & PGI-C Response were also in favor of valbenazine treatment. The results will be presented at a medical conference in 2022
- The treatment-emergent AEs were consistent with the known safety profile of valbenazine, no suicidal behavior was observed. The company is planning to submit sNDA to the US FDA in 2022
Ref: PR Newswire | Image: Neurocrine
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].